Antibiotice Ia (ATB) - Total Assets
Based on the latest financial reports, Antibiotice Ia (ATB) holds total assets worth RON1.55 Billion RON (≈ $356.95 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ATB cash generation efficiency for how efficiently the company converts equity into cash flow.
Antibiotice Ia - Total Assets Trend (2020–2025)
This chart illustrates how Antibiotice Ia's total assets have evolved over time, based on quarterly financial data. See Antibiotice Ia (ATB) stock price for real-time trading data and today's change.
Antibiotice Ia - Asset Composition Analysis
Current Asset Composition (September 2025)
Antibiotice Ia's total assets of RON1.55 Billion consist of 36.3% current assets and 63.7% non-current assets. Explore Antibiotice Ia (ATB) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (RON) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RON0.00 | 0.7% |
| Accounts Receivable | RON339.09 Million | 24.4% |
| Inventory | RON182.34 Million | 13.1% |
| Property, Plant & Equipment | RON0.00 | 0.0% |
| Intangible Assets | RON69.95 Million | 5.0% |
| Goodwill | RON0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Antibiotice Ia's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Antibiotice Ia's current assets represent 36.3% of total assets in 2025, a decrease from 43.5% in 2020.
- Cash Position: Cash and equivalents constituted 0.7% of total assets in 2025, down from 0.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 24.4% of total assets.
Antibiotice Ia Competitors by Total Assets
Key competitors of Antibiotice Ia based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.89 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.73 Billion |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401
|
China | CN¥5.91 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
China | CN¥3.34 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Antibiotice Ia - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.25 | 2.27 | 2.16 |
| Quick Ratio | 0.80 | 1.50 | 1.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | RON121.56 Million | RON351.38 Million | RON201.72 Million |
Antibiotice Ia - Advanced Valuation Insights
This section examines the relationship between Antibiotice Ia's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.34 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 8.9% |
| Total Assets | RON1.39 Billion |
| Market Capitalization | $308.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Antibiotice Ia's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Antibiotice Ia's assets grew by 8.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Antibiotice Ia (2020–2025)
The table below shows the annual total assets of Antibiotice Ia from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | RON1.39 Billion ≈ $319.75 Million |
+8.86% |
| 2024-09-30 | RON1.28 Billion ≈ $293.74 Million |
+12.30% |
| 2023-09-30 | RON1.14 Billion ≈ $261.57 Million |
+33.01% |
| 2022-09-30 | RON856.47 Million ≈ $196.66 Million |
-4.35% |
| 2021-09-30 | RON895.39 Million ≈ $205.60 Million |
+3.75% |
| 2020-09-30 | RON863.00 Million ≈ $198.16 Million |
-- |
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more